Holen Sie sich die Stockscreener-App
108.28
1.78%
2.12
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt GILD?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Gilead Sciences Inc Aktie (GILD) Neueste Nachrichten
Tomas Cihlar, Gilead Sciences, Named to TIME’s List of 100 Most Influential People in the World for HIV Research - ACCESS Newswire
Gilead Sciences Inc. stock outperforms competitors on strong trading day - MarketWatch
Unusual Options Alert: The Smart Money Is Piling Into Gilead Sciences (GILD) - Barchart.com
Gilead Sciences: Buy Rating Affirmed Amid Promising Lenacapavir Approval and Market Expansion - TipRanks
Gilead Sciences discovers new PRMT5 inhibitors - BioWorld MedTech
Gilead Sciences, Inc. (GILD) and Kite to Present Breakthrough Cancer Therapy Data at 2025 ASCO and EHA - Yahoo Finance
Insider Sell: Andrew Dickinson Sells Shares of Gilead Sciences I - GuruFocus
Gilead Sciences (GILD) is Flashing a Quant Signal That Wall Street is Ignoring - Money Morning
Gilead Sciences: Bringing PBC Into Focus Through Art of Patient Stories - CSRwire
Gilead and Kite Announce Presentation of Transformative Data in 1L Metastatic Triple-Negative Breast Cancer, Updated Results in Multiple Myeloma and Early Data From Novel Investigational CAR T-Cell Therapy Targeting Brain Cancer at 2025 ASCO and E - BioSpace
Does Gilead's drug lenacapavir have the power to end the AIDS epidemic?San Francisco Business Times - The Business Journals
Gilead and Kite Announce Presentation of Transformative Data in 1L Metastatic Triple-Negative Breast Cancer, Updated Results in Multiple Myeloma and Early Data From Novel Investigational CAR T-Cell Th - GuruFocus
Gilead And Kite Announce Presentation Of Transformative Data In 1L Metastatic Triple-Negative Breast Cancer, Updated Results In Multiple Myeloma And Early Data From Novel Investigational CAR T-Cell Therapy Targeting Brain Cancer At 2025 ASCO And - marketscreener.com
Does Gilead's latest PreP drug lenacapavir have the power to end the AIDS epidemic?San Francisco Business Times - The Business Journals
Upcoming Meeting for GILD in Foster City | GILD Stock News - GuruFocus
Is Trending Stock Gilead Sciences, Inc. (GILD) a Buy Now? - Yahoo Finance
Statutory Profit Doesn't Reflect How Good Gilead Sciences' (NASDAQ:GILD) Earnings Are - simplywall.st
What Are Wall Street Analysts' Target Price for Gilead Sciences Stock? - MSN
ADPHC and Gilead Sciences Ireland sign MoU to strengthen public health collaboration in Abu Dhabi - ZAWYA
The 2024 Responsible Business and Impact Report Shares How Gilead Sciences Is Driving Change - CSRwire
Gilead Sciences Is Overvalued Now (Rating Downgrade) - Seeking Alpha
Why Gilead Sciences (GILD) Is Among the Best Pharma Stocks to Invest in Amid the Domestic Manufacturing Boom - Insider Monkey
Gilead at Bank of America 2025: Strategic Focus on HIV Innovation - Investing.com
Non-radiographic Axial Spondyloarthritis Market on Track for Major Expansion by 2032, According to DelveInsight | Novartis, Jiangsu HengRui Medicine, Eli Lilly, UCB Biopharma, Gilead Sciences, Pfizer - Barchart.com
Galapagos gets cold feet over plans to split up company - Fierce Biotech
Integrase Inhibitors Market Key Players AnalysisGilead - openPR.com
Gilead Sciences Clears Technical Benchmark, Hitting 90-Plus RS Rating - Investor's Business Daily
Trump executive order demands pharma industry price cuts - marketscreener.com
Thermo Fisher, Biogen, Gilead Sciences, Moderna, and QuidelOrtho Stocks Trade Up, What You Need To Know - MSN
Gilead Plans Another $11B Investment in U.S. Drug Production - AdvancedManufacturing.org
Trump signs executive order to demand pharma industry cuts prices - marketscreener.com
Trump calls for broad drug price cuts in executive order, wants at least 59% drop - marketscreener.com
Trump calls for broad drug price cuts in executive order - marketscreener.com
The Zacks Analyst Blog Highlights Disney, Gilead Sciences, Eaton and Maui Land & Pineapple - Yahoo Finance
GILD Q1 Earnings Call: HIV Growth and Pipeline Momentum Offset Revenue Miss - Yahoo Finance
Biopharma Targets an HIV Cure as NIH Funding Cuts Threaten To Derail Progress - BioSpace
Gilead boosts planned US investments by $11 billion amid tariff threat - AOL.com
Is Gilead Sciences (GILD) Among the Best Stocks to Buy According to Jim Simons’ Renaissance Technologies? - Insider Monkey
Top Analyst Reports for Walt Disney, Gilead Sciences & Eaton - Yahoo Finance
Gilead Sciences Inc. stock underperforms Friday when compared to competitors - MarketWatch
Earth Day Focus for Gilead Sciences – Every Action Has an Impact - CSRwire
Merus annonce ses résultats financiers pour le premier trimestre 2025 et fait le point sur ses activités - GlobeNewswire Inc.
Cancer Research Center Celebrates Topping-Out of New Foster City Facility - San Francisco YIMBY
Decoding Gilead Sciences Inc (GILD): A Strategic SWOT Insight - GuruFocus
Gilead Sciences (GILD) Announces Results of 2025 Annual Stockholders Meeting - GuruFocus
Gilead Sciences Holds Annual Stockholders Meeting - TipRanks
Gilead Joins Pharma’s US Investment Rush - insights.citeline.com
Gilead Sciences holds annual stockholders meeting - Investing.com
Gilead Announces $32 Billion Investment Into US Drug Manufacturing - Pharmaceutical Online
1.41%
0.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):